Abstract
Background
Recent experimental evidence has shown a potential role of interleukin (IL)-11 and its receptor in breast cancer development and progression. However, there is little clinical information to support this hypothesis. We examined the expression of IL-11 and its receptor in primary breast cancer tissue samples and correlated their level of expression with the clinical outcome.
Methods
Primary breast cancer samples (n = 109) and matched background tissue obtained from patients in the cohort (n = 33) were processed for frozen section and RNA extraction. Frozen sections from matched tissues were immunostained with IL-11 and IL-11 receptor antibodies. Staining intensity was analyzed by computer image analysis. RNA was reverse-transcribed and quantified before analysis by quantitative polymerase chain reaction. Results were expressed as the number of transcripts (standardized by β-actin). The data were compared with the clinical outcome of the disease.
Results
The intensity of staining for both IL-11 and the IL-11 receptor was distinctly high in tumor samples (P < .01). The transcript level of IL-11 was significantly higher in node-positive tumor samples compared with node-negative samples (P = .02). Tumors with a poor prognostic index and poor histological grade showed a higher level of IL-11. A higher level of IL-11 was linked to poorer survival with Kaplan-Meier survival analysis.
Conclusions
IL-11 can be a predictor of poor prognosis in human breast cancer.
Similar content being viewed by others
References
Pisani P, Parkin DM, Ferlay J. Estimates of worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 1993; 55:891–903
Van ‘t Veer LJ, Dai H, Van De Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415:530–6
Kang Y, Seigel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3:537–49
Crichton MB, Nichols JE, Zhao Y, Bulun SE, Simpson ER. Expression of transcript of interleukin-6 and related cytokines by human breast tumours, breast cancer cells and adipose stromal cells. Mol Cell Endocrinol 1996; 118:215–20
Douglas AM, Goss GA, Sutherland RL, et al. Expression and function of members of the cytokine receptor superfamily on breast cancer cells. Oncogene 1997; 14:661–9
Morinaga Y, Fujita N, Ohishi K, Zhang Y, Tsuruo T. Suppression of interleukin-11 mediated bone resorption by cyclooxygenase inhibitor. J Cell Physiol 1998; 175:247–54
Lacroix M, Siwek B, Marie PJ, Body JJ. Production and regulation of interleukin-11 by breast cancer cells. Cancer Lett 1998; 127:29–35
Manolagas SC, Jilka RL. Bone marrow, cytokines and remodelling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995; 332:305–11
Guise TA, Mundy GR. Cancer and bone. Endocr Rev 1998; 19:18–54
Arguello F, Baggs RB, Frantz CN. A murine model of experimental metastasis to bone and bone marrow. Cancer Res 1988; 48:6876–81
Morgan H, Tumber A, Hill PA. Breast cancer cells induce osteoclast formation by stimulating host IL-11 production and down regulating granulocyte/macrophage colony-stimulating factor. Int J Cancer 2004; 109:653–60
Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham prognostic index in primary breast cancer. Breast Cancer Res Treat 1992; 22:207–19
Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. 1. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19:403–10
Chomczynske P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:156–9
Jiang WG, Watkins G, Lane J, et al. Prognostic value of Rho family and rho-GDIs in breast cancer. Clin Cancer Res 2003; 9:6432–40
Martin TA, Goyal A, Watkins G, Jiang WG. Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Ann Surg Oncol 2005; 12:1–9
Davies G, Jiang WG, Mason MD. Cell–cell adhesion and signaling intermediates in human prostate cancer. J Urol 2000; 163:985–92
King JAC, Ofori-Acquash AF, Stevens T, Al-Mehdi AB, Fodstad O, Jiang WG. Prognostic value of ALCAM in human breast cancer. Breast Cancer Res 2004; 6:478–87
Paul SR, Bennett F, Calvotti JA, et al. Molecular cloning of a cDNA encoding interleukin-11, a stromal cell-derived lymphopoietic and hematopoietic cytokine. Proc Natl Acad Sci USA 1990; 87:7512–6
Du X, Williams DA. Interleukin-11: review of molecular, cell biology and clinical use. Blood 1997; 89:3897–908
Sotiriou C, Lacroix M, Lespagnard L, Larsimont D, Paesmans M, Body JJ. Interleukin-6 and -11 expression in primary breast cancer and subsequent development of bone metastasis. Cancer Lett 2001; 169:87–95
Acknowledgments
The authors are grateful to Cancer Research Wales and to Breast Cancer Campaign, Cardiff, for their support to carry out this research work.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hanavadi, S., Martin, T.A., Watkins, G. et al. Expression of Interleukin 11 and Its Receptor and Their Prognostic Value in Human Breast Cancer. Ann Surg Oncol 13, 802–808 (2006). https://doi.org/10.1245/ASO.2006.05.028
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/ASO.2006.05.028